BioCentury
ARTICLE | Company News

Swedish Orphan Biovitrum deal

April 9, 2012 7:00 AM UTC

Swedish Orphan agreed to settle the remaining development and milestone obligations owed to the former stockholders of Arexis AB, which Swedish Orphan acquired in 2005. Swedish Orphan will pay to the former stockholders SEK77 million ($11.7 million), including SEK36 million ($5.5 million) up front, and will not have any future milestone obligations for Arexis' fat malabsorption product Kiobrina ( BSSL). Additionally, Swedish Orphan will pay SEK20 million ($3 million) next year and SEK21 million ($3.2 million) in 2014. Kiobrina, a recombinant human bile salt-stimulated lipase (rhBSSL), is in Phase III testing in premature infants. ...